Maxim Group LLC is acting as sole book-running manager of the proposed offering.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APRE:
- Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
- Aprea Therapeutics announces Phase II SBIR award from NCI
- Aprea Therapeutics announces one-for-twenty reverse stock split
- Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
- Aprea Therapeutics appoints John Hamill as Chief Financial Officer